ВМІСТ IL-1B, IL-4, IL-6, IL-10, TNF-α ТА IFNΓ В ПУХЛИНАХ РАКУ СЕЧОВОГО МІХУРА ЗАЛЕЖНО ВІД СТУПЕНЯ ГІСТОЛОГІЧНОЇ ДИФЕРЕНЦІАЦІЇ ЗЛОЯКІСНИХ ПУХЛИН

Abstract

Bladder cancer (BC) is the 9th most commonly diagnosed cancer worldwide, with the highest rates in developed countries. About ¾ of the patients are men. The risk of developing of malignancies increases with chronic inflammation. Chronic inflammation can be caused by infections, autoimmune diseases and other factors. In conditions of chronic inflammation, cytokines are involved in leukocyte recruitment due to enhanced expression of cell adhesion molecules and chemoattraction. Cytokines are involved in the inflammatory response, for example, they are the main determinants of cellular infiltration, cellular activation and systemic response to inflammation. It is now well established that the role of cytokines is to participate in many aspects of biology, including malignancies. Cytokines can be secreted not only by proinflammatory cells but also by stromal cells and malignant cells, thus establishing a network with various factors that may be involved in the development of BC. The progression of BC causes an imbalance between local and general immunity. The relationship between neoplastic cells and their microenvironment is essential in the proliferation and invasion of malignant cells. The purpose of this work was to determine the content of cytokines IL-1b, IL-4, IL-6, IL-10, TNF-α and IFNγ in tumor tissues, depending on the grade of cell differentiation. In our study the content of IL-1b, IL-4, IL-6, IL-10 was higher in the wall samples of bladder cancer tissues in patients with G3-4 grade BC, which may be an important characteristic of malignant cells in BC, and explain the high invasiveness of BC. The content of TNF-α, IFNγ did not significantly change depending on grade. The data of our study are consistent with the data of previous studies conducted in the study of other neoplasms, which indicate the relationship of the studied indicators with the development of cancer.